- Trials with a EudraCT protocol (155)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
155 result(s) found for: Cortex.
Displaying page 1 of 8.
EudraCT Number: 2009-018209-32 | Sponsor Protocol Number: DHEA091209 | Start Date*: 2010-02-17 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: EFFECTS OF DHEA TREATMENT ON ANTHROPOMETRIC AND METABOLIC PARAMETERS, AND ON QUALITY OF LIFE (QOL) IN PATIENTS WITH ADDISON S DISEASE UNDER GLUCORTICOID-MINERALCORTICOID SUBSTITUTIVE TREATMENT | |||||||||||||
Medical condition: Addison s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004758-27 | Sponsor Protocol Number: V1 | Start Date*: 2013-01-30 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Augenheilkunde | ||
Full Title: fMRI analysis of the visual cortex in neovascular age-related macular degeneration | ||
Medical condition: 20 patients with neovascular age-related macular degeneration will be examined before and after 3 monthly administered intravitreal ranibizumab injections according to the label with 7 tesla magnet... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004769-15 | Sponsor Protocol Number: V1.2 | Start Date*: 2013-12-13 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Augenheilkunde | ||
Full Title: fMRI analysis of the visual cortex in neovascular Age-related Macular Degeneration | ||
Medical condition: 20 patients with neovascular age-related macular degeneration will be examined before and after 3 monthly administered intravitreal ranibizumab injections according to the label with 3 tesla magnet... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002151-10 | Sponsor Protocol Number: NEUROPROTECTpost-CA | Start Date*: 2015-08-07 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: Neuroprotective goal directed hemodynamic optimization in post-cardiac arrest patients: a randomized controlled trial (the NEUROPROTECT post-CA trial) | |||||||||||||
Medical condition: post-cardiac arrest patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001682-33 | Sponsor Protocol Number: 6176/RADS2 | Start Date*: 2012-09-06 | |||||||||||||||||||||
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||||||||||||
Full Title: Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Disease | |||||||||||||||||||||||
Medical condition: Autoimmune Addison's disease: autoimmune primary adrenal insufficiency | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012820-97 | Sponsor Protocol Number: OSI-906-301 | Start Date*: 2009-12-29 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma | |||||||||||||
Medical condition: Adrenocortical Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007262-38 | Sponsor Protocol Number: ADIUVO | Start Date*: 2008-03-12 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA | |||||||||||||
Full Title: Efficacy of adjuvant mitotane treatment in prolonging disease-free survival in patients with adrenocortical cacinoma submitted to radical resection | |||||||||||||
Medical condition: PATIENTS WITH ADRENOCORTICAL CARCINOMA SUBMITTED TO RARICAL SURGERY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001165-15 | Sponsor Protocol Number: SIRAC-1 | Start Date*: 2007-06-08 | |||||||||||
Sponsor Name:University Hospital of Wuerzburg | |||||||||||||
Full Title: Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC) | |||||||||||||
Medical condition: Adrenocortical Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014810-87 | Sponsor Protocol Number: CL2-NEURO-005 | Start Date*: 2010-07-22 |
Sponsor Name:INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | ||
Full Title: Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity induced by paired associative stimulation using transcranial magnetic stimulation (TMS) in patients sufferi... | ||
Medical condition: - Patients suffering from Mild Cognitive Impairment (memory problems, objective memory disorder, absence of other cognitive disorders or repercussions on daily life, normal general cognitive functi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-018074-56 | Sponsor Protocol Number: G0900001:RoSAv1.1:12_09 | Start Date*: 2010-05-05 | |||||||||||
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Revival of autochthonous adrenocortical stem cells in autoimmune Addison’s disease (RoSA) | |||||||||||||
Medical condition: Autoimmune Addison's disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003062-18 | Sponsor Protocol Number: 4071 | Start Date*: 2008-06-05 | |||||||||||
Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust | |||||||||||||
Full Title: Immunotherapeutic Rescue of steroidogenic function in autoimmune Addison’s Disease (RAD): Pilot study | |||||||||||||
Medical condition: Autoimmune Addison's disease (adrenocortical failure) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006121-65 | Sponsor Protocol Number: 65411807 | Start Date*: 2021-08-31 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: STUDY PROTOCOL: A multi-centre, randomized, double-blinded, placebo controlled 1-year study to compare the effect of hydrocortisone and palcebo in patients with partial adrenal insufficiency after ... | |||||||||||||
Medical condition: To investigate the effects of hydrocortisone replacement in participants with previous PMR and GCA, who are in GC-free remission and exhibit biochemical evidence of mild to moderate adrenal insuffi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001212-30 | Sponsor Protocol Number: ECEP-BPD | Start Date*: 2018-09-18 | |||||||||||
Sponsor Name:Central Institute of Mental Health, represented by commercial and administrative Director | |||||||||||||
Full Title: A trial to study effects of a single dose Citalopram on emotion processing in female patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals | |||||||||||||
Medical condition: Borderline Personality Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002528-18 | Sponsor Protocol Number: RESCUE2131PE9 | Start Date*: 2022-02-22 | |||||||||||
Sponsor Name:Copenhagen University Hospital Rigshospitalet | |||||||||||||
Full Title: RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency; A multicentre, randomised, double blinded, placebo-controlled clinical trial on health-re... | |||||||||||||
Medical condition: Glucocorticoid-induced adrenal insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000494-91 | Sponsor Protocol Number: PEMBR-01 | Start Date*: 2022-12-22 | |||||||||||
Sponsor Name:Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Państwowy Instytut Badawczy | |||||||||||||
Full Title: A multicentre, open-label phase 2 study to evaluate the efficacy and safety of pembrolizumab in the treatment of advanced, progressive adrenocortical carcinoma. | |||||||||||||
Medical condition: carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000580-90 | Sponsor Protocol Number: ASSTBS-ONCO-ACACIA-18 | Start Date*: 2018-06-20 | |||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized | |||||||||||||
Medical condition: localized Adrenocortical CarcInomA with high risk of recurrence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000945-29 | Sponsor Protocol Number: ASSTBS-ONCO-ABACUS-16 | Start Date*: 2016-06-16 | |||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) | |||||||||||||
Medical condition: Cushing’s syndrome in patients with adrenocortical carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004530-38 | Sponsor Protocol Number: ASSTBS-FARONCO-PESETA-20 | Start Date*: 2022-05-30 | |||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENALCORTICAL (PESETA TRIAL) | |||||||||||||
Medical condition: advanced/ metastatic patients with ACC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004137-18 | Sponsor Protocol Number: CO-ACT-001 | Start Date*: 2007-10-19 | |||||||||||
Sponsor Name:Collaborative group for Adrenocortical Carcinoma Therapy (COAT) [...] | |||||||||||||
Full Title: First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) | |||||||||||||
Medical condition: chemotherapy with etoposide, doxorubicin and cisplatin plus mitotane (EDP/M) as first line treatment versus streptozotocin plus mitotane (Sz/M) as first line treatment in advanced and Metastatic Ad... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013355-29 | Sponsor Protocol Number: SCH/09/018 | Start Date*: 2010-07-02 | ||||||||||||||||
Sponsor Name:Sheffield Children's NHS Foundation Hospital | ||||||||||||||||||
Full Title: A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered synacthen and salivary cortisol. The validated non-invasive SST will be used to establish... | ||||||||||||||||||
Medical condition: In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establi... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.